Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01852942 · ClinicalTrials.gov registry record · Phase 2
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
A Phase 2 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT01852942 is a Phase 2 study that has completed, run by University of Minnesota. The registered enrollment target is 52 participants.
The verdict
NCT01852942, a Phase 2 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
This study was designed to test the hypothesis that treatment of HIV infected subjects with losartan, an agent with specific anti-inflammatory and anti-fibrotic actions, will: 1. reverse existing lymphoid tissue fibrosis, 2. restore lymphoid tissue architecture, 3. increase the number and improve the function of peripheral and lymphatic CD4 T cells, 4. decrease levels of systemic immune activation (IA), 5. decrease size of the HIV reservoir, and 6. be safe and well tolerated.
Interventions
- DRUG Placebo
- DRUG Losartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2014-09 |
| Est. Completion | 2019-07-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01852942
The ClinicalTrials.gov registry entry for NCT01852942 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01852942 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01852942 about?
NCT01852942 is a clinical study titled "Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV". This study was designed to test the hypothesis that treatment of HIV infected subjects with losartan, an agent with specific anti-inflammatory and anti-fibrotic actions, will: 1. reverse existing lymphoid tissue fibrosis, 2. restore lymphoid tissue architecture, 3. increase the number and improve t...
What is the current status of trial NCT01852942?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2014-09. Estimated completion is 2019-07-16.
What interventions are being tested in trial NCT01852942?
The interventions under investigation include: Placebo (DRUG), Losartan (DRUG).
Who is sponsoring clinical trial NCT01852942?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.